Is Aurora Cannabis (TSX:ACB) Poised for a Stunning Rebound?

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is trading for less than half its book value. If the company survives and recovers beyond this crisis, the upside could be over 162%.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It’s been a rough few years for Canada’s cannabis sector. A lack of a recognizable brand, oversupply of dried marijuana, supply chain issues, and boardroom scandals have destroyed billions in market value across the sector. Edmonton-based Aurora Cannabis (TSX:ACB)(NYSE:ACB) has suffered more than most. Now, it could be on the verge of a rebound. 

Cannabis outlook

Many of the cannabis sector’s biggest issues seem to have been resolved. Shareholders have pushed out early founders and restructured management teams to provide better oversight. Meanwhile, the price for legal recreational marijuana has dipped and is much closer to the black market price per ounce. 

The sudden spike in demand for cannabis in recent months has helped clear much of the oversupply. Cannabis use jumped 19% from February 2020 to March 2020 alone. Adult users turned to the drug, as the economy shut down and everyone was confined to their homes. 

Now, this usage could accelerate with the roll out of Cannabis 2.0 products. Edible candy and cannabis-infused drinks open up market opportunities on several new fronts. These products are easier to consume and could encourage non-smokers to adopt the hobby. 

It’s the perfect tailwind for companies like Aurora Cannabis to regain lost ground. 

Aurora Cannabis stock

Once an industry titan, Aurora Cannabis has lost roughly 90% of its market value since March, 2019. That’s over $15 billion in shareholder wealth destruction in less than two years. 

However, the current stock price looks oversold. Consider the fact that the company’s book value per share is $35.8, while the stock price is languishing at $13.7. In other words, the stock is just 38% of book value. 

Also consider that Aurora’s debt-to-equity ratio is just 15.2%, and its cash pile is $242 million. In other words, it’s in good financial shape to survive for several years till it regains ground. Meanwhile, the team is using this cash to expand further. With the recent acquisition of Reliva, Aurora Cannabis seems to have entered the U.S. market. 

Aurora’s existing brands, including Aurora Drift and Aurora Aces, are starting to gain traction with consumers. 

If the team can successfully turn things around and sustain this steady pace of growth, the stock could rapidly rebound to at least its book value. That implies 163% upside from the current market price. Furthermore, the ongoing turmoil in the cannabis sector could eliminate some of the smallest and weakest players in the industry. This paves the way for potential survivors, like Aurora, to consolidate the market. 

Bottom line

It’s been a difficult few years for Canada’s cannabis sector. Nearly every company in the industry has lost a substantial amount of market value in recent months.

Aurora Cannabis, along with the rest of the recreational and medical marijuana sector, has lost tremendous value. However, the cannabis trade is far from dead. Usage was substantially higher during the lockdown, and the company itself is in good financial shape. 

Aurora’s book value should represent fair value for the stock. If the stock rebounds to this level, some investors could be in for a 162% gain. That should be reason enough to place this stock on your radar. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »